OTC$LIANY
Lianbio-Adr · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
LianBio reported financial results for Q4 2022 and provided a corporate update, highlighting progress in clinical trials and commercial agreements.
LianBio reported a net loss of $18.3 million for the fourth quarter of 2022, compared to a net loss of $21.2 million for the same period in 2021. The company's cash, cash equivalents, and marketable securities totaled $302.4 million, providing a cash runway through the end of 2024. Key milestones anticipated in 2023 include topline data from the Phase 3 EXPLORER-CN trial of mavacamten and the Phase 3 LIBRA trial of TP-03.
- Phase 3 trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) is ongoing, with data expected mid-year 2023.
- Phase 3 registrational trial of TP-03 in Chinese patients with Demodex blepharitis is ongoing, with data expected in the fourth quarter of 2023.
- LianBio entered into a commercial agreement with Pfizer, with Pfizer opting into LianBio rights to RSV therapeutic candidate sisunatovir in LianBio territories.
- Cash, cash equivalents, and marketable securities totaled $302.4 million, providing a cash runway through the end of 2024.
Headline financials
Revenue & EPS history
Lianbio-Adr · Revenue · Quarterly
$0
Forward guidance
LianBio anticipates several key milestones in 2023, including reporting topline data from the Phase 3 EXPLORER-CN trial of mavacamten and the Phase 3 LIBRA trial of TP-03, as well as filing a New Drug Application (NDA) in 2023 to support regulatory approval of mavacamten in China.
Tailwinds
- Expected topline data from Phase 3 EXPLORER-CN trial of mavacamten in mid-2023.
- Planned NDA filing for mavacamten in China in 2023.
- Expected topline data from Phase 3 LIBRA trial of TP-03 in Q4 2023.
- Planned initiation of a Phase 1 clinical trial of BBP-398 in combination with an EGFR-inhibitor in non-small cell lung cancer in the second half of 2023.
- Planned initiation of a pivotal Phase 2 trial of infigratinib in locally advanced or metastatic gastric cancer patients with FGFR2 gene amplification in the first half of 2024 to support regulatory approval in China.
Headwinds
- Uncertainty regarding the successful initiation and conduct of planned clinical trials.
- Dependence on leveraging data generated in partners’ global registrational trials.
- Risk of competition from other biotechnology and pharmaceutical companies.
- Impact of changing laws and regulations.
- Potential delays in obtaining regulatory approval for product candidates.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports · overlaid with Q4 2022
+8.4%
Avg return
Earnings day
+8.4%
Avg return
5 days after
-3.1%
Avg return
30 days after
77%
10 / 13 earnings
Positive
+17.7%
Q4 2020
Best reaction
-4.1%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2024 | -2.2% | -6.7% | -7.4% | |
| Q3 2023 | +0.7% | +1.5% | +4.2% | |
| Q2 2023 | +2.7% | +0.0% | -9.7% | |
| Q1 2023 | -4.1% | +4.6% | +17.7% | |
| Q4 2022 | -1.2% | +17.4% | +18.0% | |
| Q3 2022 | +17.5% | +38.9% | +7.1% | |
| Q2 2022 | +11.1% | -1.5% | -3.0% | |
| Q1 2022 | +9.3% | +29.8% | +28.4% | |
| Q4 2021 | +3.9% | +26.1% | +7.3% | |
| Q2 2021 | +17.7% | +0.4% | -17.3% | |
| Q3 2021 | +17.7% | +0.4% | -17.3% | |
| Q4 2020 | +17.7% | +0.4% | -17.3% | |
| Q1 2021 | +17.7% | -2.4% | -50.4% | |
| Q3 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro